Pharmaceuticals - North America (NAFTA) Industry Guide

Date: December 1, 2012
Pages: 91
Price:
US$ 795.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PA2263FE3C5EN
Leaflet:

Download PDF Leaflet

Pharmaceuticals - North America (NAFTA) Industry Guide
Introduction

The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Features and benefits
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA pharmaceuticals market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market
  • Leading company profiles reveal details of key pharmaceuticals market players’ NAFTA operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts
  • Compares data from the US, Canada and Mexico, alongside individual chapters on each country
Highlights

The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of $298.2 billion in 2011.The Mexico was the fastest growing country, with a CAGR of 5.5% over the 2007-11 period.

Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $262.7 billion in 2011. This was followed by Canada and Mexico, with a value of $23.0 and $12.6 billion, respectively.

The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $299.5 billion in 2016, followed by Canada and Mexico with expected values of $26.9 and $17.7 billion, respectively.

Your key questions answered
  • What was the size of the NAFTA pharmaceuticals market by value in 2011?
  • What will be the size of the NAFTA pharmaceuticals market in 2016?
  • What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitors in the NAFTA pharmaceuticals market?
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
NAFTA Pharmaceuticals
Industry Outlook
Pharmaceuticals in Canada
    Market Overview
    Market Data
    Market Segmentation
    Market outlook
    Five forces analysis
    Macroeconomic indicators
Pharmaceuticals in Mexico
    Market Overview
    Market Data
    Market Segmentation
    Market outlook
    Five forces analysis
    Macroeconomic indicators
Pharmaceuticals in The United States
    Market Overview
    Market Data
    Market Segmentation
    Market outlook
    Five forces analysis
    Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology

LIST OF TABLES

Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2007-16
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2007-11
Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2011-16
Table 4: Canada pharmaceuticals market value: $ billion, 2007–11
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2011
Table 6: Canada pharmaceuticals market share: % share, by value, 2011
Table 7: Canada pharmaceuticals market value forecast: $ billion, 2011–16
Table 8: Canada size of population (million), 2007–11
Table 9: Canada gdp (constant 2000 prices, $ billion), 2007–11
Table 10: Canada gdp (current prices, $ billion), 2007–11
Table 11: Canada inflation, 2007–11
Table 12: Canada consumer price index (absolute), 2007–11
Table 13: Canada exchange rate, 2007–11
Table 14: Mexico pharmaceuticals market value: $ billion, 2007–11
Table 15: Mexico pharmaceuticals market geography segmentation: $ billion, 2011
Table 16: Mexico pharmaceuticals market share: % share, by value, 2011
Table 17: Mexico pharmaceuticals market value forecast: $ billion, 2011–16
Table 18: Mexico size of population (million), 2007–11
Table 19: Mexico gdp (constant 2000 prices, $ billion), 2007–11
Table 20: Mexico gdp (current prices, $ billion), 2007–11
Table 21: Mexico inflation, 2007–11
Table 22: Mexico consumer price index (absolute), 2007–11
Table 23: Mexico exchange rate, 2007–11
Table 24: United States pharmaceuticals market value: $ billion, 2007–11
Table 25: United States pharmaceuticals market geography segmentation: $ billion, 2011
Table 26: United States pharmaceuticals market share: % share, by value, 2011
Table 27: United States pharmaceuticals market value forecast: $ billion, 2011–16
Table 28: United States size of population (million), 2007–11
Table 29: United States gdp (constant 2000 prices, $ billion), 2007–11
Table 30: United States gdp (current prices, $ billion), 2007–11
Table 31: United States inflation, 2007–11
Table 32: United States consumer price index (absolute), 2007–11
Table 33: United States exchange rate, 2007–11
Table 34: Johnson & Johnson: key facts
Table 35: Johnson & Johnson: key financials ($)
Table 36: Johnson & Johnson: key financial ratios
Table 37: Pfizer Inc.: key facts
Table 38: Pfizer Inc.: key financials ($)
Table 39: Pfizer Inc.: key financial ratios
Table 40: AstraZeneca PLC: key facts
Table 41: AstraZeneca PLC: key financials ($)
Table 42: AstraZeneca PLC: key financial ratios
Table 43: Eli Lilly and Company: key facts
Table 44: Eli Lilly and Company: key financials ($)
Table 45: Eli Lilly and Company: key financial ratios
Table 46: Pfizer Inc.: key facts
Table 47: Pfizer Inc.: key financials ($)
Table 48: Pfizer Inc.: key financial ratios
Table 49: GlaxoSmithKline Plc: key facts
Table 50: GlaxoSmithKline Plc: key financials ($)
Table 51: GlaxoSmithKline Plc: key financials (?)
Table 52: GlaxoSmithKline Plc: key financial ratios
Table 53: Johnson & Johnson: key facts
Table 54: Johnson & Johnson: key financials ($)
Table 55: Johnson & Johnson: key financial ratios
Table 56: Pfizer Inc.: key facts
Table 57: Pfizer Inc.: key financials ($)
Table 58: Pfizer Inc.: key financial ratios
Table 59: GlaxoSmithKline Plc: key facts
Table 60: GlaxoSmithKline Plc: key financials ($)
Table 61: GlaxoSmithKline Plc: key financials (?)
Table 62: GlaxoSmithKline Plc: key financial ratios
Table 63: Merck & Co., Inc.: key facts
Table 64: Merck & Co., Inc.: key financials ($)
Table 65: Merck & Co., Inc.: key financial ratios

LIST OF FIGURES

Figure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2007-16
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2007-11
Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2011-16
Figure 4: Canada pharmaceuticals market value: $ billion, 2007–11
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 6: Canada pharmaceuticals market share: % share, by value, 2011
Figure 7: Canada pharmaceuticals market value forecast: $ billion, 2011–16
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2011
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2011
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2011
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2011
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2011
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2011
Figure 14: Mexico pharmaceuticals market value: $ billion, 2007–11
Figure 15: Mexico pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 16: Mexico pharmaceuticals market share: % share, by value, 2011
Figure 17: Mexico pharmaceuticals market value forecast: $ billion, 2011–16
Figure 18: Forces driving competition in the pharmaceuticals market in Mexico, 2011
Figure 19: Drivers of buyer power in the pharmaceuticals market in Mexico, 2011
Figure 20: Drivers of supplier power in the pharmaceuticals market in Mexico, 2011
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2011
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2011
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2011
Figure 24: United States pharmaceuticals market value: $ billion, 2007–11
Figure 25: United States pharmaceuticals market geography segmentation: % share, by value, 2011
Figure 26: United States pharmaceuticals market share: % share, by value, 2011
Figure 27: United States pharmaceuticals market value forecast: $ billion, 2011–16
Figure 28: Forces driving competition in the pharmaceuticals market in the United States, 2011
Figure 29: Drivers of buyer power in the pharmaceuticals market in the United States, 2011
Figure 30: Drivers of supplier power in the pharmaceuticals market in the United States, 2011
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2011
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2011
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2011
Figure 34: Johnson & Johnson: revenues & profitability
Figure 35: Johnson & Johnson: assets & liabilities
Figure 36: Pfizer Inc.: revenues & profitability
Figure 37: Pfizer Inc.: assets & liabilities
Figure 38: AstraZeneca PLC: revenues & profitability
Figure 39: AstraZeneca PLC: assets & liabilities
Figure 40: Eli Lilly and Company: revenues & profitability
Figure 41: Eli Lilly and Company: assets & liabilities
Figure 42: Pfizer Inc.: revenues & profitability
Figure 43: Pfizer Inc.: assets & liabilities
Figure 44: GlaxoSmithKline Plc: revenues & profitability
Figure 45: GlaxoSmithKline Plc: assets & liabilities
Figure 46: Johnson & Johnson: revenues & profitability
Figure 47: Johnson & Johnson: assets & liabilities
Figure 48: Pfizer Inc.: revenues & profitability
Figure 49: Pfizer Inc.: assets & liabilities
Figure 50: GlaxoSmithKline Plc: revenues & profitability
Figure 51: GlaxoSmithKline Plc: assets & liabilities
Figure 52: Merck & Co., Inc.: revenues & profitability
Figure 53: Merck & Co., Inc.: assets & liabilities

Ask Your Question

Pharmaceuticals - North America (NAFTA) Industry Guide
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: